Keen vs. Hims: how the two testosterone programs actually compare

This page compares Keen Testosterone Spray Rx and Hims' testosterone offering on the dimensions that matter most: delivery method, dosing, transfer risk, monitoring cadence, and clinical model. Both are telehealth-prescribed treatments; the differences are in how the medication reaches your bloodstream and how the program supports you over time. Direct-to-consumer pricing changes frequently; current pricing on either site supersedes anything quoted here.

How each program delivers testosterone

Keen prescribes a once-daily topical transdermal spray (Hypospray® delivery platform). Two sprays applied to the upper chest each morning. Each spray delivers 0.20 mL of the patient's prescribed concentration (50, 75, or 100 mg/mL).

Hims prescribes weekly intramuscular testosterone cypionate injections through its telehealth network. Patients self-administer at home, typically once weekly into the thigh or glute.

The clinical implication of this difference: transdermal sprays produce relatively flat serum testosterone curves; weekly intramuscular injections produce a pronounced peak shortly after the dose and a trough at the end of the week. The pharmacokinetic difference matters for mood stability, libido pattern, and how steady week-to-week energy feels. Neither curve is "better" universally; many patients tolerate weekly injections well, and many prefer the steadier transdermal profile.

Transfer risk

Topical and transdermal testosterone has a boxed warning regarding secondary exposure to women and children through skin-to-skin contact. The risk is largest with topical gels because the medication remains on the skin surface for hours before absorption.

Keen's Hypospray formulation is designed to dry rapidly after application. Patients are instructed to wash hands after application and to allow the spray site to dry before contact with others. Specific transfer-risk guidance is reviewed during the clinical intake.

Hims' intramuscular injections do not carry topical transfer risk because the medication is delivered directly into muscle tissue.

This is a real difference for parents of small children or anyone in close skin contact with a partner soon after the morning application window. Talk to your prescriber about what fits your living situation.

Dosing flexibility

Keen prescribes three concentrations (50, 75, 100 mg/mL) and titrates by changing concentration or changing spray count based on lab results. Adjustments happen at the prescribing physician's discretion.

Hims typically prescribes weekly injection volumes (commonly 0.5 mL of 200 mg/mL = 100 mg/week, with adjustments up or down based on labs). Adjustments happen at the prescribing physician's discretion.

Both programs require periodic lab work (testosterone, hematocrit, PSA where indicated, estradiol where indicated). The cadence depends on your clinical situation, not the platform.

Clinical model

Both Keen and Hims use independent telehealth medical practices that employ licensed clinicians prescribing under each state's telehealth rules. Both work with compounding pharmacies to fulfill prescriptions in the states where they operate.

Keen operates the Hypospray® topical platform across a specific list of states (currently 30). The medical practice partner is identified in Keen's Privacy Policy and HIPAA Notice.

Hims operates a broader telehealth platform across many product categories (hair, ED, mental health, weight loss, plus TRT). Their medical practice partner is identified in their privacy disclosures.

Neither platform employs the prescribing physicians directly; both are technology-and-coordination platforms working with independent medical practices.

What's the same

• Both are doctor-prescribed. Neither is an over-the-counter testosterone booster.
• Both require biochemically confirmed hypogonadism (low morning testosterone + symptoms) for prescription, per applicable clinical guidelines.[3]
• Both follow the same 2025 FDA labeling guidance for testosterone products.[1] The TRAVERSE trial result (no increase in major adverse cardiovascular events vs. placebo in symptomatic hypogonadal men with elevated CV risk) applies to both classes of delivery.[2]
• Both require periodic monitoring labs. The monitoring cadence is set by the prescribing physician based on your specific risk profile.

What's different at a glance

• Delivery: Keen = topical spray; Hims = weekly intramuscular injection.
• PK curve: Keen = relatively flat; Hims = weekly peak and trough.
• Transfer risk: Keen = managed via dry-after-application protocol; Hims = no topical transfer risk.
• Application cadence: Keen = two sprays daily; Hims = one injection weekly.
• Comfort: Keen = no needles; Hims = self-injection.

Which is right for you?

The honest answer is "talk to the prescribing physician on either platform." A symptomatic 38-year-old man with two children under five and a topical-transfer concern will reach a different recommendation than a 55-year-old single man with a strong needle tolerance and a preference for once-weekly cadence. Both delivery routes work; the question is which fits your physiology, your routine, and your risk profile.

If you're undecided, the lowest-stakes way to compare is to start with the platform whose delivery method you'd actually adhere to — adherence dominates outcome over a 12-month horizon in every published TRT registry. The most effective testosterone protocol is the one you actually use as prescribed.

Next steps

• Take Keen's eligibility check and get matched with a licensed prescriber if you're in one of the 30 supported states.
• Read TRAVERSE Main Trial: The Definitive Cardiovascular Safety Study to understand the modern cardiovascular safety evidence for both delivery routes.
• Read What good TRT actually looks like for a clinician's view of effective treatment regardless of delivery method.

References

3 sources

1. U.S. Food and Drug Administration. FDA issues class-wide labeling changes for testosterone products. February 28, 2025. fda.gov
2. Lincoff AM, Bhasin S, Flevaris P, et al. Cardiovascular Safety of Testosterone-Replacement Therapy. N Engl J Med. 2023;389(2):107–117. doi:10.1056/NEJMoa2215025 · PMID 37326322
3. Bhasin S, Brito JP, Cunningham GR, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(5):1715–1744. doi:10.1210/jc.2018-00229 · PMID 29562364

---

Comparison written by the Keen Clinician Team. Pricing and program details for either platform can change without notice; consult each provider's current site for live terms. This article is informational; it is not medical advice. Talk to a licensed physician before starting or changing any treatment.